Clinical Trials Education Center
About Clinical Trials
Clinical trials for pulmonary fibrosis treatment are research studies that explore whether a medical strategy, treatment, or device is safe and effective for humans. These studies also may show which medical approaches work best for certain illnesses or groups of people. Clinical trials for pulmonary fibrosis treatment produce the best data available for health care decision making.
The purpose of clinical trials is research, so the studies follow strict scientific standards. These standards protect patients and help produce reliable study results.
Enrolling Now! The PRECISIONS Study
PRECISIONS is a study that aims to transform the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) by moving it into the era of precision medicine.
With new technologies, scientists may be able to isolate and analyze patients’ precise genetic and molecular differences. The PRECISIONS study will use this approach to determine whether well-tolerated N-Acetyl-cysteine (NAC) is an effective treatment in a subset of patients with IPF who carry a particular gene variant.
The study seeks to enroll 200 participants with IPF who are 40-years old and above with a confirmed rs3570920 TT TOLLIP genotype.
Drug Development Pipeline for PF & IPF
In the PF Drug Development Pipeline you can learn about the latest in drug development for PF-related conditions. Use the filters on the left-hand side to narrow results by study phase, intervention type, condition, and more.
Phases of Clinical Trials
Clinical trials investigate dosage, safety, efficacy and potential outcomes of drugs or treatments in disease-specific populations through controlled trials. There are typically three stages or phases of clinical trials that must be performed before a drug or treatment may be submitted to regulatory agencies (ie: U.S. Food & Drug Administration) for approval. Prior to commencing a clinical trial, a drug must have demonstrated safety and efficacy in a laboratory model.
Researchers test a new drug or treatment in a small group of people (usually 20-100 volunteers) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects. Doses start small and increase in different patient groups until the desired effect of the treatment is observed or side effects of the treatment become too severe.
The drug or treatment is given to a larger group of people (up to several hundred volunteers) to see if it is effective and to further evaluate its safety. Most Phase 2 studies have randomized control (placebo) groups and treatment groups. Most of these trials are “double-blind” which means that neither the patients nor the researchers know whether the patient is receiving the treatment or placebo.
The drug or treatment is given to large groups of people (several hundred to thousands of volunteers) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments (or placebo), and collect information that will allow the drug or treatment to be used safely. Phase 3 trials are also randomized and most are double-blind.
The drug or treatment has been FDA approved for marketing. These studies can include post-market requirement and commitment studies that are required of or agreed to by the study sponsor. Phase 4 trials gather additional information about a drug's safety, efficacy, or optimal use.